has a history of sars-cov or sars-cov-2 infection, or close contact with sars-cov-2 infected persons (nucleic acid test positive) or living abroad within 30 days before screening; positive sars-cov-2 antibody test; previous history of allergy to acetaminophen or vaccination; has a history of covid-19 vaccination, or have received other inactivated or recombinant vaccines within 7 days, or received live attenuated vaccines within 14 days,before the first dose; has a medical history or family history of epilepsy, convulsions, neurological diseases and psychiatric diseases; is contraindicative for intramuscular injection; has known or suspected severe diseases by the judgement of investigators. has chronic diseases which at the discretion of investigator are inappropriate for participation; has known immunocompromised conditions diagnosed in hospital before enrollment, or functional aspleen or splenectomy caused by any condition; for women of childbearing potential: positive pregnancy test, being in pregnancy or breastfeeding, or have a pregnancy plan within one year; is participating in other clinical trials or plan to participate in other clinical trials during the study period; has received immune enhancement or immunosuppressive therapy within 3 months before the first dose of vaccine (continuous oral or instillation for more than 14 days); or received whole blood, plasma and immunoglobulin therapy within one month; is unlikely to adhere to the study procedures or keep appointments at the discretion of the investigators;or plan to permanently relocate before the end of study; or plan to leave the resident location for a long time at the scheduled visit; or has any other conditions that are inappropriate for participation for this study.

has a history of sars-cov or sars-cov-2 infection, or close contact with sars-cov-2 infected persons (nucleic acid test positive) or living abroad within 30 days before screening; positive sars-cov-2 antibody test; previous history of allergy to acetaminophen or vaccination; has a history of covid-19 vaccination, or have received other inactivated or recombinant vaccines within 7 days, or received live attenuated vaccines within 14 days,before the first dose; has a medical history or family history of epilepsy, convulsions, neurological diseases and psychiatric diseases; is contraindicative for intramuscular injection; has known or suspected severe diseases by the judgement of investigators. has chronic diseases which at the discretion of investigator are inappropriate for participation; has known immunocompromised conditions diagnosed in hospital before enrollment, or functional aspleen or splenectomy caused by any condition; for women of childbearing potential: positive pregnancy test, being in pregnancy or breastfeeding, or have a pregnancy plan within one year; is participating in other clinical trials or plan to participate in other clinical trials during the study period; has received immune enhancement or immunosuppressive therapy within 3 months before the first dose of vaccine (continuous oral or instillation for more than 14 days); or received whole blood, plasma and immunoglobulin therapy within one month; is unlikely to adhere to the study procedures or keep appointments at the discretion of the investigators;or plan to permanently relocate before the end of study; or plan to leave the resident location for a long time at the scheduled visit; or has any other conditions that are inappropriate for participation for this study.